Phase II Clinical Trial – Epilepsy
Satipharm 50mg CBD Gelpell® capsules (PTL-101) have been used in a Phase II clinical trial treating patients with treatment-resistant epilepsy (TRE). The results of the trial are stated below and published here.
The safety, tolerability, and effectiveness of PTL-101 (Satipharm 50mg CBD Gelpell® capsules), an oral cannabidiol formulation, in pediatric intractable epilepsy: A phase II, open-label, single-center study.
- PTL-101 (Satipharm 50mg CBD Gelpell® capsules) is a unique oral formulation containing highly purified cannabidiol.
- This work assessed the efficacy of PTL-101 in patients with treatment-resistant epilepsy.
- PTL-101 proved safe and tolerable in patients with epilepsy and significantly reduced seizure frequency.
- PTL-101 promises to enhance patient well-being, increase patient adherence and compliance.
Several works have reported on the antiepileptic impact of cannabis-based preparations in patients with treatment-resistant epilepsy (TRE). However, current formulations suffer from low bioavailability and side effects. PTL-101, an oral formulation containing highly purified cannabidiol (CBD) embedded in seamless gelatin matrix beadlets was designed to enhance bioavailability and maintain a constant gastrointestinal transit time.
This phase II, prospective study was open to pediatric patients with TRE on stable antiepileptic drugs' (AEDs) doses, who experienced ≥ 4 seizures within four weeks of enrolment and with a history of ≥ 4 AEDs failing to provide seizure control. Following a 4-week observation period, patients began a 2-week dose-titration phase (up to ≤ 25 mg/kg or 450 mg, the lower of the two), followed by a 10-week maintenance treatment period. Caregivers recorded seizure frequency, type, and severity and ranked their global impressions after 7 and 12 weeks of treatment. Responders were those showing a ≥ 50% reduction from baseline monthly seizure frequency. Safety assessments monitored vital signs, adverse effects, physical and neurological exams, and laboratory tests.
Sixteen patients (age: 9.1 ± 3.4) enrolled in the study; 11 completed the full treatment program. The average maintenance dose was 13.6 ± 4.2 mg/kg. Patient adherence to treatment regimens was 96.3 ± 9.9%. By the end of the treatment period, 81.9% and 73.4 ± 24.6% (p < 0.05) reductions from baseline median seizure count and monthly seizure frequency, respectively, were recorded. Responders' rate was 56%; two patients became fully seizure-free. By study end, 8 (73%) caregivers reported an improved/very much improved condition, and 9 (82%) reported reduced/very much reduced seizure severity. Most commonly reported treatment-related adverse effects were sleep disturbance/insomnia, (4 (25.0%) patients), followed by somnolence, increased seizure frequency, and restlessness (3 patients each (18.8%)). None were serious or severe, and all resolved.
PTL-101 was safe and tolerable for use and demonstrated a potent seizure-reducing effect among pediatric patients with TRE.
This is a research study only and is not intended to promote the use of Satipharm CBD Gelpell® capsules for any medical condition.